These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35787399)

  • 41. Overexpression of the ∆Np73 isoform is associated with centrosome amplification in brain tumor cell lines.
    Mikulenkova E; Neradil J; Zitterbart K; Sterba J; Veselska R
    Tumour Biol; 2015 Sep; 36(10):7483-91. PubMed ID: 25910708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway.
    Wilhelm MT; Rufini A; Wetzel MK; Tsuchihara K; Inoue S; Tomasini R; Itie-Youten A; Wakeham A; Arsenian-Henriksson M; Melino G; Kaplan DR; Miller FD; Mak TW
    Genes Dev; 2010 Mar; 24(6):549-60. PubMed ID: 20194434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
    Emmrich S; Wang W; John K; Li W; Pützer BM
    Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
    Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
    Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
    Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
    Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
    Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
    Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.
    Kim SR; Lewis JM; Cyrenne BM; Monico PF; Mirza FN; Carlson KR; Foss FM; Girardi M
    Oncotarget; 2018 Jun; 9(49):29193-29207. PubMed ID: 30018745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
    Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
    Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential regulation of TP73 isoforms by 1α,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas.
    Díaz R; González-Sancho JM; Soldevilla B; Silva J; García JM; García V; Peña C; Herrera M; Gómez I; Bonilla F; Domínguez G
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1135-42. PubMed ID: 20842728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
    Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
    Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
    Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mammary epithelial cell polarity is regulated differentially by p73 isoforms via epithelial-to-mesenchymal transition.
    Zhang Y; Yan W; Jung YS; Chen X
    J Biol Chem; 2012 May; 287(21):17746-17753. PubMed ID: 22457351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.
    Litvinov IV; Cordeiro B; Huang Y; Zargham H; Pehr K; Doré MA; Gilbert M; Zhou Y; Kupper TS; Sasseville D
    Clin Cancer Res; 2014 Jul; 20(14):3799-808. PubMed ID: 24850846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer.
    Di Vinci A; Sessa F; Casciano I; Banelli B; Franzi F; Brigati C; Allemanni G; Russo P; Dominioni L; Romani M
    Int J Oncol; 2009 Feb; 34(2):449-56. PubMed ID: 19148480
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
    Qu K; Zaba LC; Satpathy AT; Giresi PG; Li R; Jin Y; Armstrong R; Jin C; Schmitt N; Rahbar Z; Ueno H; Greenleaf WJ; Kim YH; Chang HY
    Cancer Cell; 2017 Jul; 32(1):27-41.e4. PubMed ID: 28625481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.
    Hofstetter G; Berger A; Chamson M; Müller-Holzner E; Reimer D; Ulmer H; Uramoto H; Marth C; Zeimet AG; Zeillinger R; Concin N
    Int J Gynecol Pathol; 2011 Nov; 30(6):527-31. PubMed ID: 21979586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas.
    Domínguez G; Peña C; Silva J; García JM; García V; Rodríguez R; Cantos B; Citores MJ; España P; Bonilla F
    J Pathol; 2006 Dec; 210(4):390-7. PubMed ID: 17029218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.